NME Candidates For 2012 Have Modest Ambitions; Standard Reviews And Small Molecules Dominate
By
Bridget Silverman / Email the Author / Pharmaceutical Approvals Monthly February 2012, Vol. 17, No. 2
New Drug Approvals / Word Count: 3022 / Article # 06120201032
Executive Summary
With the same range of novel product submissions as in 2011, the year ahead could reach an equally healthy tally of new molecular and novel biological entity approvals. But a look at upcoming applications suggests that the makeup of those classes could be very different.
$125.00
Buy Now
For $125.00, purchase this 3022-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.